Table 1 Baseline characteristics of the included 163 patients
Variables | Total | IC* (n = 98) | IC + immunotherapy (n = 65) | p |
|---|---|---|---|---|
Age | ||||
  < 40 | 15 (9.2%) | 10 (10.2%) | 5 (7.8%) |  |
  ≥ 40 | 148 (90.8%) | 88 (89.8%) | 60 (92.2%) | 0.587 |
Sex | ||||
 Male | 113 (69.3%) | 68 (69.4%) | 45 (69.2%) |  |
 Female | 50 (30.7%) | 30 (30.6%) | 20 (30.8%) | 0.983 |
ECOG# | ||||
 0 | 75 (46.0%) | 43 (43.9%) | 32 (49.2%) |  |
 1 | 88 (54.0%) | 55 (56.1%) | 33 (50.8%) | 0.502 |
Smoker | 100 (61.3%) | 65 (66.3%) | 35 (53.8%) | 0.109 |
Drinker | 73 (44.8%) | 46 (46.9%) | 27 (41.5%) | 0.497 |
Primary site | ||||
 Oral cavity | 38 (23.3%) | 23 (23.5%) | 15 (23.1%) |  |
 Oropharynx | 56 (34.4%) | 35 (35.7%) | 21 (32.3%) |  |
 Larynx | 37 (22.7%) | 22 (22.4%) | 15 (23.1%) |  |
 Hypopharynx | 32 (19.6%) | 18 (18.4%) | 14 (21.5%) | 0.952 |
Tumor stage | ||||
 T2 | 46 (28.2%) | 26 (26.5%) | 20 (30.8%) |  |
 T3 | 63 (38.7%) | 40 (40.8%) | 23 (35.4%) |  |
 T4 | 54 (33.1%) | 32 (32.7%) | 22 (33.8%) | 0.754 |
Neck stage | ||||
 N0 | 16 (9.8%) | 10 (10.2%) | 6 (9.2%) |  |
 N1 | 48 (29.4%) | 29 (29.6%) | 19 (29.2%) |  |
 N2 | 79 (48.5%) | 43 (43.9%) | 36 (55.4%) |  |
 N3 | 20 (12.3%) | 16 (16.3%) | 4 (6.2%) | 0.223 |
Disease stage | ||||
 III | 13 (8.0%) | 8 (8.2%) | 5 (7.7%) |  |
 IV | 150 (92.0%) | 90 (91.8%) | 60 (92.3%) | 0.913 |
p16 positivity^ | 16 (28.6%) | 11 (31.4%) | 5 (23.8%) | 0.541 |
Reason for not surgery | ||||
 Refuse | 41 (25.2%) | 28 (28.6%) | 13 (20.0%) |  |
 Heavy tumor burden | 88 (54.0%) | 54 (55.1%) | 34 (52.3%) |  |
 Low physical status | 34 (20.9%) | 16 (16.3%) | 18 (27.2%) | 0.164 |